Guilherme Giorelli @drgiorelli

"There is also compelling preliminary evidence suggesting that the use of these drugs [GLP-1] could exacerbate and lead to new diagnoses of restrictive eating disorders, including anorexia nervosa." @NEJM today nejm.org/doi/full/10.10…

Reduced-frequency GLP-1 as a maintenance strategy: in this case series, patients who tapered from weekly semaglutide/tirzepatide to less frequent dosing maintained weight loss, body composition, and metabolic syndrome gains, supporting structured de-escalation to lower burden without sacrificing efficacy. onlinelibrary.wiley.com/doi/full/10.10…

New obesity guideline release 💯 American Diabetes Association Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity ADA adds to the list of guidelines published this past year summarizing the evidence of obesity medications. A particular emphasis on selecting a treatment based on the particular concurrent obesity comorbidities present. diabetesjournals.org/docm-care/arti…

Even though the 1st GLP-1 drug was approved 20 years ago, there are dozens of new molecules and combinations in the pipeline , including muscle building drugs (Table). A new @NatureMedicine review by @DanielJDrucker, a pioneer of this field. nature.com/articles/s4159…

keyboard_arrow_left Previous keyboard_arrow_right Next

Healthy Diet Plate For Weight Management On GLP-1 based therapy

We are pleased to share the online publication of the conference report from the KDIGO Controversies Conference on the Relationship Between Obesity and CKD: Pathophysiology, Prognosis, and Management. Read the full report in @Kidney_Int: kdigo.co/Obesity-CKD-Co… Read the news release: kdigo.co/Obesity-CKD-Co… The conference brought together patients and international experts in nephrology, endocrinology, epidemiology, and nutrition to examine emerging evidence and define research priorities to address the increasing global burden of obesity-related CKD. The conference was co-chaired by Dr. Susan Furth (US), and @PeterRossing (DK). “Obesity is not simply a coexisting condition in CKD; it influences kidney function across the life course,” said Dr. Furth. “Because sustained exposure to obesity beginning early in life confers risks for CKD and cardiovascular disease, there is an important need for earlier identification, improved assessment tools, and prevention strategies. Patient participants at the conference emphasized the need for patient-centered, stigma-free care delivered by a multidisciplinary team.” “Effective obesity treatment has the potential to improve kidney outcomes far beyond weight reduction alone,” said Dr. Rossing. “As with metabolic and bariatric surgery, newer pharmacologic therapies, including GLP-1 receptor agonists, can lead to meaningful weight loss and promising cardiovascular and kidney benefits. At the same time, critical evidence gaps remain around optimal timing and duration of interventions, particularly across CKD stages. Addressing these gaps will be essential to translating innovation into better kidney care.” #obesity #CKD

50 mg of oral #semaglutide daily was associated with body weight reduction and improved cardiometabolic risk factors in East Asian adults with overweight or #obesity, with or without type 2 #diabetes. ja.ma/46VkTE2

📢We are pleased to announce publication of the EASO Algorithm for the pharmacological treatment of obesity and its complications in Nature Medicine. Obesity is an adiposity-based chronic disease (ABCD); assess severity and complications to guide treatment doi.org/10.1038/s41591…

Integrating lifestyle factors like diet and physical activity with #GLP1 receptor agonists is essential for managing symptoms, maintaining nutrition, preserving lean mass, and promoting regular physical activity. ja.ma/42d846m

Weight cycling and its effects on muscle mass, sarcopenia and sarcopenic obesity (open access) doi.org/10.1007/s11154…

No one becomes a clinician to do paperwork, but it's becoming a bigger and bigger administrative burden, taking time and attention away from actually treating and supporting patients. That’s why we’re introducing Microsoft Dragon Copilot, the industry’s first AI assistant for clinical workflow.

Outro patamar? Nova era da medicina? O fato: tratar obesidade impacta em mais de 200 doenças. Você pode concordar com Musk ou não. Mas é impossível ser indiferente ao impacto dos GLP1 na saúde.

Elon Musk @elonmusk

2 years ago

Nothing would do more to improve the health, lifespan and quality of life for Americans than making GLP inhibitors super low cost to the public. Nothing else is even close.

6K 4K 37K 21.2M 5K

This is nuts! x.com/GigaBasedDad/s…

Enhanced metabolic rates help humans fuel expanded brains, faster reproductive rates, extended longevity, and high percentage of body fat pnas.org/doi/10.1073/pn…

#AHA24: New in #JACC, the CMR substudy of the #SUMMIT trial led by Dr. @ChrisKramerMD showing the effects of tirzepatide on cardiac structure and function bit.ly/3CytSPZ #HFpEF #Obesity

#AHA24: New in #JACC, a secondary analysis of the #SELECT trial looking at #semaglutide in patients with history of both #cvCABG & #obesity. Check out this infographic summarizing all SELECT studies in #JACCJournals to date bit.ly/3Of4vp8

#Exercise training refers to any movement that is intentional, structured and repetitive undertaken with the primary goal of improving health or physical fitness. A guide for patients buff.ly/3w9g3P8 @busetto_luca @farpourn @AliceBellicha @jorgeencantado @busetto_luca

New EASO guideline as published in @NLM_NIH Practice Guideline - EASO Position Statement on medical nutrition therapy for the management of individuals with overweight or obesity and cancer. pubmed.ncbi.nlm.nih.gov/39433024/

Most viewed in the last 7 days from @JAMAInternalMed: Vitamin K2 supplementation significantly reduced the frequency, intensity, and duration of nocturnal leg cramps in older adults. ja.ma/3CjRQyp